Moffitt Cancer Center | Strategic Alliance Partners

August 23, 2024

Joshua Linscott, MD, PhD, discusses a study evaluating a utDNA assay for minimal residual disease detection in patients with high-risk NMIBC.

August 22, 2024

Roger Li, MD, discusses the implications of a post hoc analysis of the KEYNOTE-057 trial in BCG-unresponsive, high-risk non–muscle-invasive bladder cancer.

August 19, 2024

Ahmad Tarhini, MD, PhD, discusses the hypothesis for investigating high-dose bolus IL-2 plus an anti–CTLA-4 agent in patients with advanced melanoma.

August 16, 2024

Ahmad Tarhini, MD, PhD, discusses the use of high-dose bolus IL-2 with ipilimumab followed by nivolumab in advanced melanoma following prior progression.

August 16, 2024

Richard Kim, MD, discusses the current treatment paradigm for patients with resectable CRC, as well as unmet needs in this population.

August 13, 2024

Roger Li, MD, details a post hoc analysis of patients with BCG-unresponsive non–muscle-invasive bladder cancer who did not respond to pembrolizumab.

August 08, 2024

Joshua Linscott, MD, PhD, discusses a study investigating the use of utDNA to predict MRD prior to rTURBT in NMIBC.

August 02, 2024

Roger Li, MD, discusses the efficacy of bladder-sparing therapy after progression on pembrolizumab in patients with BCG-unresponsive, high-risk NMIBC.

July 19, 2024

Richard Kim, MD, discusses the standard treatment approaches and unmet needs for patients with resectable colorectal cancer.

July 18, 2024

A phase 1b trial is evaluating the TIL therapy TBio-4101 plus pembrolizumab in PD-(L)1 inhibitor–resistant head and neck squamous cell carcinoma.

July 15, 2024

Kedar Kirtane, MD, discusses the design of a phase 1b trial evaluating the TIL Tbio-4101 plus pembrolizumab in patients with advanced HNSCC.

July 02, 2024

Nikhil Khushalani, MD, discusses the benefits and limitations of fixed-dose treatment regimens in patients with unresectable or metastatic melanoma.

June 24, 2024

Ahmad Tarhini, MD, PhD, discusses a prognostic model evaluating patients with advanced melanoma treated with immune checkpoint inhibitors.

June 20, 2024

Roger Li, MD, discusses patient outcomes from the KEYNOTE-057 trial in BCG–unresponsive, high-risk non–muscle-invasive bladder cancer.

June 20, 2024

Kedar Kirtane, MD, discusses a phase 1b study of TBio-4101 plus pembrolizumab in patients with PD-1 inhibitor–resistant, advanced HNSCC.

June 18, 2024

Peter Forsyth, MD, discusses the importance of evaluating leptomeningeal disease caused by TNBC and HER2+ breast cancer.

May 16, 2024

Bruna Pellini, MD, highlights the multiple immunotherapies currently available for patients with NSCLC in the perioperative setting and elucidates ctDNA’s role in the treatment paradigm.

May 10, 2024

Hannah Walker-Mimms, MS, discusses a study revealing that Ewing and clear cell sarcomas have increased sensitivity to filanesib over other cancer types.

May 10, 2024

Hye Sook Chon, MD, discusses the DUO-E trial of frontline durvalumab plus chemotherapy followed by durvalumab and olaparib in endometrial cancer.

May 05, 2024

Roger Li, MD, discusses the rationale of the phase 3 MoonRISe-1 trial (NCT06319820).